A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
about
Mechanisms of heparanase inhibitors in cancer therapy.Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management.Expression of heparanase in soft tissue sarcomas of adults.A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice.Structure and epitope distribution of heparan sulfate is disrupted in experimental lung hypoplasia: a glycobiological epigenetic cause for malformation?Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells.Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.Allele loss and down-regulation of heparanase gene are associated with the progression and poor prognosis of hepatocellular carcinoma.Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft functionStructural characterization of human heparanase reveals insights into substrate recognition.Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes.Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significancesHeparanase is overexpressed in lung cancer and correlates inversely with patient survivalAlternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasisStructure-function approach identifies a COOH-terminal domain that mediates heparanase signaling.Heparanase: busy at the cell surface.The prognostic significance of heparanase expression in metastatic melanomaHeparan sulfate in angiogenesis: a target for therapy.Down-regulation of heparanase leads to the inhibition of invasion and proliferation of A549 cells in vitro and in vivo.Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.Heparin Mimetics: Their Therapeutic Potential.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.
P2860
Q30244089-DEA61797-2254-4E72-9895-0946D24A143BQ33350614-49AD3E8C-D440-4967-BFFA-C65124D7CDCAQ33634228-47BA9B1F-FD55-4A73-B50C-671652A93106Q33752920-B1358FF7-4019-475C-90B1-98D3F95CD05FQ33879791-F32ED1B9-EB80-4F5E-BEF4-B01AD09AA813Q33932177-AD5FDB08-E625-4360-A14F-2DC4F6E20E11Q34061158-7EE99B27-8F4B-4F63-A95C-A6FFBED30256Q34398151-4AADAB5A-6820-4B4B-B245-7FF147A21503Q34406172-517D9329-D0D8-412D-8529-20B3915186E6Q34426913-B73DE609-BA0B-41ED-BC24-D4F7949B9615Q34501966-F55BD60C-19B4-4BD6-9BDF-5EEE07A9F0C3Q34802543-30836BFB-27FD-4D0C-B8BA-2D180F851C22Q35640553-BFB5DB4A-FE23-4050-A8D6-46DF18694922Q35707564-67AA0401-8D39-4D7A-A0C9-1057DE7BE8E7Q37059154-87A33D1F-CC16-44D4-B753-493019D9D13DQ37114794-D14F77B9-2E2D-4E02-B988-A7093C26C322Q37116228-AA978A64-4D67-4338-99EC-FD7454931816Q37371146-0A8E34F2-491A-4ADF-8BD5-A8EC84E83D75Q37688833-8A66D5D4-A070-49F7-A46E-E14565EF4923Q38154506-9F5790FC-B9DF-443B-9D5C-A1BF5F7C75B9Q39225944-EBEBE593-2CF5-49A0-9ADE-F6F763F7FAF5Q42224130-60C9BE06-99B4-4E6A-A0B0-A4515A4B0F1EQ43171467-1E987B6C-937E-4BEF-B969-DAF54BC15881Q47159791-395C5DBB-1A7B-4AE2-9378-6B1E1B2DD363Q48171089-91C037E1-474E-4F1B-9C6C-B0A1757A5A58
P2860
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@ast
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@en
type
label
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@ast
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@en
prefLabel
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@ast
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@en
P2093
P1476
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
@en
P2093
Alex Powell
Andrew M Haydon
Brian R Creese
Damien B Thomson
John R Zalcberg
Karl D Lewis
Kaye L Roberts
Michael J Millward
Rene Gonzalez
William A Robinson
P2888
P356
10.1007/S10637-007-9080-5
P577
2007-09-20T00:00:00Z
P6179
1016118104